Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.

Mease, Philip J; Karki, Chitra; Liu, Mei; Kavanaugh, Arthur; Ritchlin, Christopher T; Huynh, Doquyen Hoa; Palmer, Jacqueline B; Greenberg, Jeffrey D

Mease, Philip J; Karki, Chitra; Liu, Mei; Kavanaugh, Arthur; Ritchlin, Christopher T; Huynh, Doquyen Hoa; Palmer, Jacqueline B; Greenberg, Jeffrey D.

Afiliación

Mease PJ; Rheumatology Clinical Research Division, Swedish Medical Center and University of Washington, Seattle, Washington, USA.
Karki C; Corrona, Waltham, Massachusetts, USA.
Liu M; Corrona, Waltham, Massachusetts, USA.
Kavanaugh A; University of California San Diego, San Diego, California, USA.
Ritchlin CT; Allergy, Immunology and Rheumatology Division, University of Rochester Medical Center, Rochester, New York, USA.
Huynh DH; Scripps Health, San Diego, California, USA.
Palmer JB; Novartis Pharmaceuticals, East Hanover, New Jersey, USA.
Greenberg JD; Corrona, Waltham, Massachusetts, USA.

RMD Open ; 4(1): e000638, 2018.

Article en En | MEDLINE | ID: mdl-29707232

Palabras clave

biologic disease-modifying antirheumatic drugs; index biologic; minimal disease activity; observational study; psoriatic arthritis

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Tipo de estudio: Risk_factors_studies Idioma: En Revista: RMD Open Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google